Understanding Amvuttra®
Amvuttra® (vutrisiran) is an RNA interference (RNAi) therapy used to treat hereditary transthyretin-mediated (hATTR) amyloidosis, a rare genetic disease characterized by the buildup of abnormal protein deposits (amyloid)that can lead to nerve damage (polyneuropathy) and organ dysfunction. By reducing transthyretin (TTR) protein levels, Amvuttra® slows disease progression, improves nerve function, mobility, and quality of life, and requires less frequent dosing than other therapies. This effective and convenient option helps manage symptoms and slow the progression of nerve damage in patients with hATTR amyloidosis.
How Amvuttra® Works:
- Targets and reduces TTR protein levels, preventing amyloid buildup.
- Slows the progression of nerve damage, improving overall function.
- Requires less frequent dosing, enhancing treatment convenience.
FDA Approval:
- Amvuttra® (vutrisiran): Approved in 2022.
For more information, please visit the Amvuttra® patient website and speak with your healthcare provider to determine if Amvuttra® is the right treatment option for you.
